2025 BLOOM BURTON & CO. HEALTHCARE INVESTOR CONFERENCE



Metro Toronto Convention Centre May 5 & 6, 2025

BLOOM BURTON & CO. EXISTS TO ACCELERATE RETURNS IN THE HEALTHCARE SECTOR FOR BOTH COMPANIES AND INVESTORS.



THERE IS NO GREATER
ILLUSTRATION OF THE POWER
OF OUR PLATFORM THAN
THIS CONFERENCE, WHICH
HAS GROWN INTO CANADA'S
FLAGSHIP HEALTHCARE
INVESTMENT AND
NETWORKING EVENT OVER
THE PAST DECADE.

WELCOME!

Welcome to the 2025 Bloom Burton & Co. Healthcare Investor Conference!

Bloom Burton & Co. is solely dedicated to accelerating the path to monetization for healthcare companies and investors; we do so through our specialized services such as raising equity and debt capital, M&A advisory, equity research, sales and trading, strategic advisory, and principal investing, including creating and incubating new companies. We work with organizations of every stage of development and in every area of healthcare, including biotechnology, pharmaceuticals, medical technology, healthcare services, digital health, research and manufacturing tools, pharma services, as well as animal and consumer health.

There is no greater expression of the breadth of our work than the annual Bloom Burton & Co. Healthcare Investor Conference, which is Canada's flagship event for global investors to meet Canada's leading companies, and the ecosystem which supports them.

Last year, we hosted the eighth edition of the Bloom Burton Award Gala, and we are honoured once again, to bring everyone together and shine a bright light on Canadian excellence in healthcare. We look forward to seeing everyone dressed to impress in black-tie, cheering on their colleagues and collaborators at the 2025 Bloom Burton Award Gala on September 25, 2025 at The Ritz-Carlton, Toronto. This year's three finalists will be announced this week, during the lunch hour of the conference!

We are always impressed with the advancement of the healthcare industry – even during times of uncertainty – and we remain committed to serving as a force for strategic growth in our industry.

We are also proud of our brilliant and dedicated team, who work tirelessly to produce exceptional work and support positive outcomes for all of our clients. Our entire team is here for you this week as you make new connections and plan for the success of the healthcare sector in Canada and beyond.

We wish you a wonderful conference!

TABLE OF CONTENTS

ABOUT	3
AGENDA	4
KEYNOTE SPEAKER	6
INVESTING IN COMMERCIAL-STAGE HEALTHCARE COMPANIES PANEL	8
INVESTING IN R&D-STAGE HEALTHCARE COMPANIES PANEL	11
PRESENTING COMPANIES	17
ABOUT BLOOM BURTON & CO.	52
BLOOM BURTON & CO. SERVICES	54
SPONSORS	56
CONFERENCE INFORMATION	55



2025 BLOOM BURTON & CO. HEALTHCARE INVESTOR CONFERENCE



The 2025 Bloom Burton & Co. Healthcare Investor Conference takes place on May 5 & 6, 2025 at the Metro Toronto Convention Centre.

We have invited 66 of Canada's premier and most promising publicly-traded and private companies in the healthcare industry to attend and present to our audience of Canadian, U.S. and international investors.

At the conference, investors and company management have the opportunity to meet one-on-one. We also provide a stage for industry leaders to discuss the latest news and share insights on the ups and downs of the market and the state of the global healthcare industry.



Breakfast and Opening Remarks

8:30 AM

MONDAY, MAY 5

Plenary Room 106/107

REGISTRATION

9:30 AM	Toronto Stock Exchange Opening			OPENS AT 8:00 AM
	ROOM 104 C/D	ROOM 104 B	ROOM	104 A
9:30 AM	NASDAQ: ABCL AbCellera Biologics Biotechnology	TSX-V: WOLF Grey Wolf Animal Health Pharmaceutical	TSX-V: PI Perimete Medical Te	r Medical Imaging
10:00 AM	TSX-V: NGEN NervGen Pharma Biotechnology	NASDAQ: THTX, TSX: TH Theratechnologies Pharmaceutical	PRIVATE Sonic Inc Medical Te	cytes chnology
10:30 AM	NASDAQ: PMN ProMIS Neurosciences Biotechnology	TSX-V: LSL LSL Pharma Group Pharmaceutical	PRIVATE Flosonic Medical Te	s Medical chnology
11:00 AM	NASDAQ: DRUG, CSE: DRUG Bright Minds Biosciences Biotechnology	TSX: MDP Medexus Pharma Pharmaceutical	PRIVATE Intellijoii Medical Te	n t Surgical chnology
11:30 AM	TSX: MSCL Satellos Bioscience Biotechnology	TSX-V: RX BioSyent Pharmaceutical	PRIVATE Aspect B Biotechnol	iosystems ogy
12:00 PM 12:30 PM	Lunch Keynote Speaker	(D.); . O. O. D. D.	Plenary	Room 106/107
	Jim Momtazee, Managing Partn	er (Patient Square Capital)		
	ROOM 104 C/D	ROOM 104 B	ROOM	104 A
1:30 PM	ROOM 104 C/D NASDAQ: ZYME Zymeworks Biotechnology	ROOM 104 B TSX: CPH Cipher Pharmaceuticals Pharmaceutical	PRIVATE	nce Therapeutics
1:30 PM 2:00 PM	NASDAQ: ZYME Zymeworks	TSX: CPH Cipher Pharmaceuticals	PRIVATE Congrue	nce Therapeutics _{ogy}
	NASDAQ: ZYME Zymeworks Biotechnology NASDAQ: ENGN enGene	TSX: CPH Cipher Pharmaceuticals Pharmaceutical TSX: GUD Knight Therapeutics	PRIVATE Congruel Biotechnole PRIVATE Epitopea	nce Therapeutics ogy Oncology
2:00 PM	NASDAQ: ZYME Zymeworks Biotechnology NASDAQ: ENGN enGene Biotechnology TSX: MDNA Medicenna Therapeutics	TSX: CPH Cipher Pharmaceuticals Pharmaceutical TSX: GUD Knight Therapeutics Pharmaceutical TSX: HLS HLS Therapeutics	PRIVATE Congrue Biotechnol PRIVATE Epitopea Biotechnol PRIVATE Alpha-9 Biotechnol CSE: BETI	ogy Oncology Pharma
2:00 PM 2:30 PM	NASDAQ: ZYME Zymeworks Biotechnology NASDAQ: ENGN enGene Biotechnology TSX: MDNA Medicenna Therapeutics Biotechnology TSX: APS Aptose Biosciences	TSX: CPH Cipher Pharmaceuticals Pharmaceutical TSX: GUD Knight Therapeutics Pharmaceutical TSX: HLS HLS Therapeutics Pharmaceutical PRIVATE Xediton Pharmaceuticals	PRIVATE Congrue Biotechnole PRIVATE Epitopea Biotechnole PRIVATE Alpha-9 Biotechnole CSE: BETI BetterLif Biotechnole TSX-V: M	nce Therapeutics ogy Docology ogy Pharma ogy RVL liosciences
2:00 PM 2:30 PM 3:00 PM	NASDAQ: ZYME Zymeworks Biotechnology NASDAQ: ENGN enGene Biotechnology TSX: MDNA Medicenna Therapeutics Biotechnology TSX: APS Aptose Biosciences Biotechnology NASDAQ: EPRX, TSX: EPRX Eupraxia Pharmaceuticals	TSX: CPH Cipher Pharmaceuticals Pharmaceutical TSX: GUD Knight Therapeutics Pharmaceutical TSX: HLS HLS Therapeutics Pharmaceutical PRIVATE Xediton Pharmaceuticals Pharmaceutical PRIVATE FORUS Therapeutics	PRIVATE Congrue Biotechnole PRIVATE Epitopea Biotechnole PRIVATE Alpha-9 Biotechnole CSE: BETI BetterLif Biotechnole TSX-V: M Marvel E Biotechnole NASDAQ:	once Therapeutics once Therape

TUESDAY, MAY 6

8:20 AM	Breakfast and Opening Remarks	Plenary Room 106/107
8:30 AM	Investing in Commercial-Stage Healthcare Companies Panel	
	Michael Altman (Perceptive Advisors), Gerry Brunk (Lumira Venture	s),
	Adrianna Czornyj (Persistence Capital Partners), and Parag Shah (K	2 HealthVentures)

	ROOM 104 C/D	ROOM 104 B	ROOM 104 A
9:30 AM	TSX: WELL WELL Health Technologies Healthcare Services	PRIVATE Synaptive Medical Medical Technology	PRIVATE Virica Biotech Pharma Services
10:00 AM	TSX: AIDX Healwell AI Digital Health	PRIVATE MolecuLight Medical Technology	PRIVATE AtomVie Global Radiopharma Pharma Services
10:30 AM	TSX: VHI VitalHub Digital Health	PRIVATE Nicoya Lifesciences Medical Technology	PRIVATE MSH Pharma Pharma Services
11:00 AM	TSX-V: NPTH NeuPath Health Healthcare Services	PRIVATE Fluid Biomed Medical Technology	PRIVATE Entos Pharmaceuticals Biotechnology
11:30 AM	TSX: AND Andlauer Healthcare Group Healthcare Services	PRIVATE Exact Imaging Medical Technology	PRIVATE Zucara Therapeutics Biotechnology

12:00 PM Lunch

Plenary Room 106/107

12:30 PM Investing in R&D-Stage Healthcare Companies Panel

Karim Helmy (Viking Global Investors), Aaron Kantoff (Scion Life Sciences), Allyson Rinderle (Bain Capital Life Sciences), and Nimish Shah (Venrock)

	ROOM 104 C/D	ROOM 104 B	ROOM 104 A
1:30 PM	PRIVATE League Digital Health	NASDAQ: PROF, TSX: PRN Profound Medical Medical Technology	PRIVATE Ventus Therapeutics Biotechnology
2:00 PM	PRIVATE Canary Medical Medical Technology	TSX-V: COV Covalon Technologies Medical Technology	PRIVATE Find Therapeutics Biotechnology
2:30 PM	TSX-V: PCRX PharmaCorp Rx Healthcare Services	TSX: MBX Microbix Biosystems Medical Technology	PRIVATE Specific Biologics Biotechnology
3:00 PM	PRIVATE Specialty Medical Partners Healthcare Services	TSX-V: CNVI Conavi Medical Medical Technology	PRIVATE Radiant Biotherapeutics Biotechnology
3:30 PM	PRIVATE SRx Health Solutions Healthcare Services	PRIVATE Orpyx Medical Technology	PRIVATE Reverb Therapeutics Biotechnology
4:00 PM	PRIVATE XYON Health Digital Health	PRIVATE Altis Labs Pharma Services	PRIVATE Feldan Therapeutics Biotechnology

KEYNOTE SPEAKER



ABOUT JIM MOMTAZEE

Jim Momtazee is the Managing Partner of Patient Square Capital. Mr. Momtazee has 29 years of investment and acquisition experience, the vast majority of which was focused on the health care sector. Prior to Patient Square, he spent over 21 years at KKR, initially joining in 1996. He helped establish the firm's health care industry group in 2001 and subsequently was Head of the Americas Health Care Team for over 10 years. In that role, he managed a team of over 20 dedicated health care professionals overseeing five different health care-related investment strategies including private and growth equity. He was a member of the Americas Private Equity Investment Committee beginning in 2013 and was Chairman of both the Health Care Strategic Growth and Health Care Royalty & Income Investment Committees.

Among the major health care investments made during Mr. Momtazee's tenure at KKR were Jazz Pharmaceuticals (2004); HCA (2006), a \$33 billion transaction which at the time was the largest cash buyout in history; PRA Health Sciences (2013); and BridgeBio Pharma (2016).

Mr. Momtazee currently serves on the board of directors of Apollo Therapeutics, Kriya Therapeutics, Enavate Sciences, Elevage Medical Technologies, Syneos Health, GondolaBio, Hanger, Roivant Sciences, BridgeBio Pharma, and the Medical Device Manufacturers Association. He previously served on the board of directors of Ajax Health, Alliance Imaging, Arbor Pharmaceuticals, PharMerica, Covenant Surgical Partners, EchoNous, Entellus Medical, Envision Healthcare, Global Medical Response, HCA, Heartland Dental, Jazz Pharmaceuticals, Lake Region Medical, PRA Health Sciences, and Spirox.

Earlier in his career, Mr. Momtazee was one of three executives who moved to London to launch KKR's European investing operations and also spent several months helping launch Accel-KKR, a software and technology-enabled services investment firm. Prior to KKR, Mr. Momtazee worked at Donaldson, Lufkin & Jenrette and was involved in a broad range of merchant banking, M&A, debt, equity, and restructuring transactions.

Mr. Momtazee received a B.A. with distinction, Phi Beta Kappa, from Stanford University and an M.B.A., Arjay Miller Scholar, from Stanford's Graduate School of Business.



INVESTING IN COMMERCIAL-STAGE HEALTHCARE **COMPANIES PANEL**

MICHAEL ALTMAN

Perceptive Advisors

GERRY BRUNK

Lumira Ventures

ADRIANNA CZORNYJ

Persistence Capital Partners

PARAG SHAH

K2 HealthVentures

Tuesday, May 6, 2025 8:30 AM - 9:30 AM Plenary Room 106/107



INVESTING IN COMMERCIAL-STAGE HEALTHCARE COMPANIES PANEL



MICHAEL ALTMAN
Head of Strategy
Perceptive Advisors

Michael Altman joined Perceptive in 2007 and is the Head of Strategy on the investment team. His focus is on medical devices, diagnostics, digital health and Specialty Pharmaceuticals. He is also a member of the investment committee for the Credit Opportunities Fund. Additionally, Michael serves as the CFO and Director of ARYA Sciences Acquisition Corp II & III. Prior to Perceptive he was a healthcare trader and analyst at First New York Securities. Michael graduated from the University of Vermont with a B.S. in Business Administration



GERRY BRUNK
Managing Director
Lumira Ventures

Gerry Brunk is a co-founder and Managing Director of Lumira Ventures, a healthcare venture capital firm. Based in the firm's Boston office, he has led investments in over thirty biotechnology and medical device companies including MAKO Surgical, HistoSonics, Pharmasset, Endotronix, SpectraWAVE, Cardiac Dimensions, enGene, Cadence Neuroscience, Endogenex, and Bardy Diagnostics. Prior to beginning his venture capital career in 2002 Gerry was a founder of several venture capital-funded healthcare companies, served in the healthcare practice at Boston Consulting Group, and was a member of the investment banking group at Credit Suisse First Boston.

Gerry holds an MBA from Stanford University Graduate School of Business and a BA from the University of Virginia where he studied biology and economics.

INVESTING IN COMMERCIAL-STAGE HEALTHCARE COMPANIES PANEL



ADRIANNA CZORNYJ
Partner

Persistence Capital Partners

Adrianna Czornyj is a Partner at Persistence Capital Partners (PCP), a private equity firm that focuses exclusively on investments in the Canadian healthcare industry. As a Partner, Adrianna is responsible for all aspects of the investment process from sourcing, evaluating and executing on investment opportunities to managing existing investments. As a healthcare investor, Adrianna has invested in companies across Canada including homecare, animal health, aesthetic medicine & dermatology, fertility, executive health, pharmacy and health education. Adrianna has over twenty years of experience in M&A, audit, consulting, valuation and private equity. Before joining PCP, Adrianna was a Partner in Deloitte's M&A transaction services practice, where she served private equity and strategic corporate investors.

Adrianna is also involved in the community through her role as a director and past Treasurer/Chair of the Finance & Audit Committee for the Michael Garron Hospital Foundation, member of the governance committee at The York School and recently completing ten years with Crohn's and Colitis Canada as the Chair of the Board. Adrianna is also a director with the Association for Corporate Growth, Toronto Chapter.



PARAG SHAH
Founding Managing Director & CEO
K2 HealthVentures

Parag Shah has over 25 years of experience in finance, operations, and venture capital, and is highly experienced in providing comprehensive capital structure solutions to private and public companies in the life sciences industry. Parag previously served as the Senior Managing Director and Group Head of the Life Sciences practice at Hercules Capital. Over approximately 10 years, Parag and his team committed around \$2 billion in capital to venture and growth stage companies in the life sciences industry. Prior to that, Parag was Senior Vice President and Group Head of Imperial Bank's Life Sciences practice. which was acquired by Comerica Bank. He also served as an Assistant Vice President at BancBoston (acquired by Fleet), where he focused on mergers and acquisitions finance. Parag currently serves as Chairman of eCare Vault, an early-stage software company that bridges privacy-compliant communications between the education and health sectors. He is also a charter member of TiE. one of the leading entrepreneurial organizations in the country.

Parag is a graduate of MIT where he received an M.S. in Technology, Management, and Policy and B.S. in Molecular Biology, and continues to be involved with the Whitehead Institute at MIT.

INVESTING IN R&D-STAGE HEALTHCARE **COMPANIES PANEL**

KARIM HELMY

Viking Global Investors

AARON KANTOFF

Scion Life Sciences

ALLYSON RINDERLE

Bain Capital Life Sciences

NIMISH SHAH

Venrock

Tuesday, May 6, 2025 12:30 PM - 1:30 PM Plenary Room 106/107



INVESTING IN R&D-STAGE HEALTHCARE COMPANIES PANEL



KARIM HELMY
Managing Director

Viking Global Investors

Karim Helmy is a Managing Director focused on the healthcare sector on the private equity team.

Prior to joining Viking in 2020, Karim was a Vice President at Venrock and an Engagement Manager at McKinsey & Company in the Pharmaceuticals Research & Development Practice.

Karim received a joint M.D./Ph.D. from New Jersey Medical School and completed an internship in Internal Medicine at Columbia University Medical Center. Before medical school, he worked in discovery research at Genentech. Karim received a B.S. in biology from Stanford University.



AARON KANTOFF

Managing Partner
Scion Life Sciences

Aaron Kantoff is a founder and Managing Partner of Scion. He has spent 15 years specializing in founding, building and investing in life sciences companies, focusing primarily on therapeutics. Aaron currently serves as a board member of Avalo Therapeutics and Tourmaline Bio, where he has been serving since the company's inception. Previously, he was a Venture Partner at Medicxi, where he was a founding board member of Centessa Pharmaceuticals PLC. Before joining Medicxi, he was a co-founder and board member of RayzeBio, which was acquired by Bristol Myers Squibb.

From 2011 until 2019, Aaron was a Partner at Apple Tree Partners (ATP), a life sciences venture capital firm. At ATP, Aaron was a key member of the therapeutics investment practice, playing a leading role in assembling several ATP portfolio companies, and most notably, serving on the boards of Akero Therapeutics, Corvidia Therapeutics (acquired by Novo Nordisk) and Syntimmune (acquired by Alexion). During his time at ATP, Aaron was also a board observer at Stoke Therapeutics and led many of ATP's crossover and public biotech investments. Before joining ATP in 2011, Aaron held various roles in private equity and investment banking. Aaron received a B.S. in Finance and International Business from NYU Stern's School of Business.

INVESTING IN R&D-STAGE HEALTHCARE COMPANIES PANEL



ALLYSON RINDERLE

Managing Director **Bain Capital Life Sciences**

Allyson S. Rinderle is a Managing Director at Bain Capital Life Sciences, having joined the fund in 2022.

Prior to joining Bain Capital, Allyson was a Principal at KKR within the Healthcare Growth Equity and Private Equity teams where she focused on the life sciences. Before KKR, Allyson was a Vice President at Longitude Capital, a healthcare venture growth firm where she focused on biopharmaceutical investments. Prior to that, Allyson was an Analyst at Aisling Capital, a life sciences investment firm, as well as an Analyst in J.P. Morgan's Health Care Investment Banking practice.

Allyson Rinderle holds an M.B.A. from Stanford Graduate School of Business, where she was an Arjay Miller Scholar. She received her B.S. in Biomedical Engineering with distinction from Yale University graduating magna cum laude, Tau Beta Pi, and Phi Beta Kappa.



NIMISH SHAH

Partner


Venrock

Nimish Shah has been investing in healthcare companies since 2010, with a sharp focus on small-cap public and crossover-stage biotech companies since joining Venrock in 2013. He has a proven track record of delivering strategic capital and market insight to help public biotech companies navigate critical inflection points.

Nimish is the co-founder and Board Director of Apogee Therapeutics and currently serves as a Board Observer for Jade Therapeutics and Timberlyne Therapeutics. His experience also includes roles as Board Director for InstilBio and as Board Observer for Biohaven Pharmaceuticals, Dianthus Therapeutics, LianBio, Metsera, and Viridian Therapeutics.

With a strong foundation in science and market dynamics, Nimish works closely with biotech CEOs to support their growth and success, including the transition from private to public company status. He holds a B.S. in pharmacy from Rutgers, an MPH from Columbia University, and an MBA from Columbia Business School, where he also serves on the Healthcare and Pharmaceutical Management Advisory Board.





NOTES

PRESENTING COMPANIES



This year's Bloom Burton & Co. Healthcare Investor Conference hosts 66 of Canada's premier and most promising publicly-traded and private companies in the healthcare industry in the following six areas.

BIOTECHNOLOGY
PHARMACEUTICAL
MEDICAL TECHNOLOGY
PHARMA SERVICES
HEALTHCARE SERVICES
DIGITAL HEALTH

ABCELLERA BIOLOGICS

Monday, May 5, 2025 | 9:30 AM Room 104 C/D



AbCellera discovers and develops antibody medicines for indications across therapeutic areas, including cancer, metabolic and endocrine conditions, and autoimmune disorders. AbCellera's engine integrates technology, data science, infrastructure, and interdisciplinary teams to solve the most challenging antibody discovery problems. AbCellera is focused on advancing an internal pipeline of first-in-class and best-in-class programs and collaborating on innovative drug development programs with partners.

BIOTECHNOLOGY

PRIVATE

ALPHA-9 ONCOLOGY

Monday, May 5, 2025 | 2:30 PM Room 104 A



Alpha-9 Oncology Inc. is a clinical stage radiopharmaceutical company developing differentiated and highly targeted radiopharmaceuticals with the potential to meaningfully improve the treatment of people living with cancer. Applying proprietary technologies and deep foundational expertise, Alpha-9 is on the forefront of engineering bespoke radiopharmaceuticals that are optimized to selectively deliver radiation to tumor sites while minimizing off-target effects. Alpha-9 is advancing a robust pipeline of novel radiopharmaceuticals with a systematic approach to molecule design that offers broad potential for expansion into several validated oncology targets.

ALTIS LABS

Tuesday, May 6, 2025 | 4:00 PM Room 104 B

ALTIS LABS

Altis Labs is the computational imaging company accelerating clinical trials with Al. Altis has trained proprietary Al models on the industry's largest multimodal training database spanning over 200 million longitudinal images linked to clinical, molecular, and outcomes data. Top 20 biopharma use Altis' Al models to more confidently analyze data from phase 1-4 clinical trials so that they can bring the most effective novel treatments to patients sooner.

HEALTHCARE SERVICES

TSX: AND

ANDLAUER HEALTHCARE GROUP

Tuesday, May 6, 2025 | 11:30 AM Room 104 C/D



AHG is a leading and growing supply chain management company offering a robust platform of customized third-party logistics ("3PL") and specialized transportation solutions for the healthcare sector. The Company's 3PL services include customized logistics, distribution and packaging solutions for healthcare manufacturers across Canada. AHG's specialized transportation services in Canada, including air freight forwarding, ground transportation, dedicated delivery and last mile services, provide a one-stop shop for clients' healthcare transportation needs. Through its complementary service offerings, available across a coast-to-coast distribution network, AHG strives to accommodate the full range of its clients' specialized supply chain needs on an integrated and efficient basis. The Company also provides specialized ground transportation services, primarily to the healthcare sector, across the 48 contiguous U.S. states.

BIOTECHNOLOGY TSX: APS

APTOSE BIOSCIENCES

Monday, May 5, 2025 | 3:00 PM Room 104 C/D



Aptose Biosciences is a clinical-stage biotechnology company committed to developing precision medicines addressing unmet medical needs in oncology, with an initial focus on hematology. The Company's small molecule cancer therapeutics pipeline includes products designed to provide single agent efficacy and to enhance the efficacy of other anti-cancer therapies and regimens without overlapping toxicities. The Company's lead clinical-stage compound tuspetinib (TUS), is an oral kinase inhibitor that has demonstrated activity as a monotherapy and in combination therapy in patients with relapsed or refractory acute myeloid leukemia (AML) and is being developed as a frontline triplet therapy in newly diagnosed AML.

BIOTECHNOLOGY

PRIVATE

ASPECT BIOSYSTEMS

Monday, May 5, 2025 | 11:30 AM **Room 104 A**



Aspect Biosystems is a biotechnology company pioneering the development of bioprinted tissue therapeutics to transform how we treat some of the most elusive diseases. Aspect's bioprinted tissue therapeutics are designed to replace, repair, or supplement biological function inside the body. Aspect is creating these next-generation cell therapies by applying its full-stack tissue therapeutic platform, which integrates proprietary Al-powered bioprinting technology, computational design tools, therapeutic cells, and advanced biomaterials. Aspect is advancing a pipeline of bioprinted tissue therapeutics across multiple disease areas in the endocrine and metabolic space including diabetes, obesity, rare endocrine disorders, and liver disease. Aspect's pipeline development strategy involves both proprietary programs as well as strategic partnerships, including a collaboration with Novo Nordisk focused on diabetes and obesity. In the past year, Aspect has entered into a CA\$200M partnership with the governments of Canada and British Columbia and closed a US\$115M Series B to support the company's progress toward the clinic.

ATOMVIE GLOBAL RADIOPHARMA

Tuesday, May 6, 2025 | 10:00 AM Room 104 A



AtomVie Global Radiopharma (AtomVie) is a global leading CDMO for the GMP manufacturing and worldwide distribution of clinical and commercial radiopharmaceuticals. AtomVie offers the full range of scientific, technical, regulatory, quality, logistics, and business expertise combined with a specialized infrastructure for the development of radiopharmaceuticals from clinical studies to the commercial marketplace. AtomVie currently serves international clients conducting studies in over 25 countries worldwide. AtomVie's new cutting-edge 72,300 sq ft facility is located in Hamilton, ON, and is set to launch in 2025.

BIOTECHNOLOGY

CSE: BETR

BETTERLIFE PHARMA

Monday, May 5, 2025 | 3:00 PM Room 104 A



BetterLife Pharma Inc. is an emerging biotechnology company primarily focused on developing and commercializing two compounds, BETR-001 and BETR-002, to treat neuro-psychiatric and neurological disorders.

BIOSYENT

Monday, May 5, 2025 | 11:30 AM Room 104 B



BioSyent is a profitable growth-oriented specialty pharmaceutical company focused on in-licensing or acquiring innovative pharmaceutical and other healthcare products that have been successfully developed, are safe and effective, and have a proven track record of improving the lives of patients. BioSyent supports the healthcare professionals that treat these patients by marketing its products through its community, specialty and international business units.

BIOTECHNOLOGY

NASDAQ: DRUG, CSE: DRUG

BRIGHT MINDS BIOSCIENCES

Monday, May 5, 2025 | 11:00 AM Room 104 C/D



Bright Minds Biosciences is a biotechnology company developing innovative treatments for patients with neurological and psychiatric disorders. Our pipeline includes novel compounds targeting key receptors in the brain to address conditions with high unmet medical need, including epilepsy, depression, and other CNS disorders. Bright Minds is focused on delivering breakthrough therapies that can transform patients' lives.

Bright Minds Biosciences has developed a unique platform of highly selective serotonergic agonists exhibiting selectivity at different serotonergic receptors. This has provided a rich portfolio of NCE programs within neurology and psychiatry.

CANARY MEDICAL

Tuesday, May 6, 2025 | 2:00 PM Room 104 C/D



Canary Medical is a medical data company focused on the development and commercialization of its patented implantable sensor technology and complementary data and analytics ecosystem. In 2021, Canary Medical introduced canturio®te, the world's first "smart knee" tibial extension, which is implanted in the body where it monitors patient activity and joint performance, and transmits data to the cloud, autonomously, requiring almost no patient compliance or physician involvement. The Company was conceived and created with the vision that healthcare transformation requires reliable and cost-effective healthcare data and that the effective monitoring and analysis of that data will produce better outcomes for patients at lower costs. Canary Medical is led by a team of experienced entrepreneurs, researchers and data scientists globally regarded for their expertise in medical device design, development and data informatics.

PHARMACEUTICAL

TSX: CPH

CIPHER PHARMACEUTICALS

Monday, May 5, 2025 | 1:30 PM Room 104 B



Cipher Pharmaceuticals is a specialty pharmaceutical company with a robust and diversified portfolio of commercial and early to late-stage products, mainly in dermatology. Cipher acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and currently markets those products in Canada, the U.S., and South America.

CONAVI MEDICAL

Tuesday, May 6, 2025 | 3:00 PM Room 104 R



Conavi Medical is focused on designing, manufacturing, and marketing imaging technologies to guide common minimally invasive cardiovascular procedures. Its patented Novasight Hybrid™ System is the first system to combine both intravascular ultrasound (IVUS) and optical coherence tomography (OCT) to enable simultaneous and co-registered imaging of coronary arteries. The Novasight Hybrid System has 510(k) clearance from the U.S. Food and Drug Administration; and regulatory approval for clinical use from Health Canada, China's National Medical Products Administration, and Japan's Ministry of Health, Labor and Welfare.

BIOTECHNOLOGY

PRIVATE

CONGRUENCE **THERAPEUTICS**

Monday, May 5, 2025 | 1:30 PM Rnnm 104 A



Congruence is a computationally-driven biotechnology company building a unique pipeline of transformative small molecule correctors rationally designed to rescue aberrant protein function. Our proprietary scalable platform, Revenir™, captures the biophysical features of proteins across their conformational ensembles, in order to identify novel allosteric and cryptic pockets which are virtually screened to generate novel chemical matter. Congruence has leveraged its proprietary discovery engine to launch a pipeline of wholly owned drugs directed to high-value, genetically validated, difficult-to-drug targets spanning a variety of indications including genetic obesity, GBA Parkinson's Disease, and α 1-Antitrypsin Deficiency. Congruence is further deploying its discovery platform to support two recently executed multi-target research collaborations with large pharmaceutical companies focused on the discovery of small molecule correctors for the treatment of solid tumors and metabolic diseases.

COSCIENS BIOPHARMA

Monday, May 5, 2025 | 4:00 PM Room 104 A



COSCIENS is a specialty biopharmaceutical company which develops and commercializes a diversified portfolio of cosmeceutical, nutraceutical and pharmaceutical products. Our technology includes proprietary extraction technology, which is applied to the production of active ingredients from renewable plant resources currently used in cosmeceutical products (i.e., oat beta glucan and avenanthramides which are found in leading skincare product brands like Aveeno and Burt's Bees formulations) and being developed as potential nutraceuticals and/or pharmaceuticals. Our consolidated portfolio also includes macimorelin (Macrilen®; Ghryvelin®), the first and only U.S. FDA and European Medicines Agency approved oral test indicated for the diagnosis of adult growth hormone deficiency ("AGHD").

MEDICAL TECHNOLOGY

TSX-V: COV

COVALON TECHNOLOGIES

Tuesday, May 6, 2025 | 2:00 PM Room 104 B



Covalon is a patient-driven medical device company, that provides innovative and cost-effective healthcare solutions for advanced wound care, infection control, and medical device coatings. Through a strong portfolio of patented technologies and solutions, we offer innovative, gentle and more compassionate options to aid patients on their healing journey. Our solutions are designed for patients and made for care providers. Covalon leverages its patented medical technology platforms and expertise in two ways: (i) by developing products that are sold under Covalon's name; and (ii) by developing and commercializing medical products for other medical companies under development and license contracts.

EDESA BIOTECH

Monday, May 5, 2025 | 4:00 PM Room 104 C/D



Edesa Biotech, Inc. is a clinical-stage biopharmaceutical company developing innovative ways to treat inflammatory and immune-related diseases. Its clinical pipeline is focused on two therapeutic areas: Medical Dermatology and Respiratory. In Medical Dermatology, Edesa is developing EB06, an anti-CXCL10 monoclonal antibody candidate, as therapy for vitiligo, a common autoimmune disorder that causes skin to lose its color in patches. Its medical dermatology assets also include EB01 (1.0% daniluromer cream), a Phase 3-ready asset developed for use as a potential therapy for moderate-to-severe chronic Allergic Contact Dermatitis. The company's most advanced Respiratory drug candidate is EB05 (paridiprubart), which is being evaluated in a U.S. government-funded platform study as a treatment for Acute Respiratory Distress Syndrome. The EB05 program has been the recipient of two funding awards from the Government of Canada to support the further development of this asset. In addition to EB05, Edesa is preparing an investigational new drug application in the United States for EB07 (paridiprubart) to conduct a future Phase 2 study in patients with pulmonary fibrosis.

BIOTECHNOLOGY

NASDAQ: ENGN

ENGENE

Monday, May 5, 2025 | 2:00 PM Room 104 C/D



enGene is a clinical-stage biotechnology company mainstreaming genetic medicines through the delivery of therapeutics to mucosal tissues and other organs, with the goal of creating new ways to address diseases with high clinical needs. enGene's mission is to deliver innovative non-viral medicines to improve the quality of life for people with urological cancers. enGene's lead program is detalimogene voraplasmid for patients with non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) – a disease with a high clinical burden – who are unresponsive or naïve to treatment with Bacillus Calmette-Guérin (BCG).

BIOTECHNOLOGY PRIVATE

ENTOS PHARMACEUTICALS



Tuesday, May 6, 2025 | 11:00 AM Room 104 A

A new reality in genetic medicine lies ahead, one that will be ushered in with the advent of safe, effective, and re-dosable nucleic acid delivery technologies. Since its inception in 2016, Entos® has been dedicated to advancing next-generation genetic medicines using our proprietary FusogenixTM PLVTM drug delivery system. The Fusogenix PLV platform is formulated with FASTTM proteins to enable the delivery of nucleic acid to target cells through direct fusion. Entos is pioneering the development of life-changing medicines for patients and has partnered with global companies, such as Eli Lilly, to accelerate and expand the impact of our platform. Entos Pharmaceuticals Inc. is headquartered in Edmonton, Canada, with its wholly owned U.S. and U.K. subsidiaries based in San Diego, California and London, United Kingdom, respectively.

BIOTECHNOLOGY

PRIVATE

EPITOPEA

Monday, May 5, 2025 | 2:00 PM Room 104 A



Epitopea is a transatlantic cancer immunotherapeutic company founded in 2021. We are developing accessible, off-the-shelf (OTS), RNA-based immunotherapies for the treatment of hard-to-treat cancers. Epitopea has generated an extensive library of aberrantly expressed, tumor specific antigens (aeTSAs), Cryptigens™ using CryptoMap™, a platform that leverages state-of-the-art immunopeptidomics, genomics, and bioinformatics. Cryptigen™ TSAs, represent a new class of tumor-specific antigens that are derived from non-canonical DNA sequences, annotated from non-coding or 'junk DNA', and are broadly shared across multiple patients. Our patient-centric commitment to transform patient outcomes via the use of OTS therapeutic vaccines is within reach, as Epitopea accelerates it first product into the clinic in Q1/2026. Epitopea is backed by leading life science investors including Advent Life Sciences, CTI Life Sciences, Cambridge Innovation Capital, Le Fonds de Solidarité FTQ, Investissement Québec, adMare BioInnovations, Jonathan Milner, the Harrington Discovery Institute, IRICoR and Novateur Ventures.

EUPRAXIA PHARMACEUTICALS



Monday, May 5, 2025 | 3:30 PM **Room 104 C/D**

Eupraxia is a clinical-stage biotechnology company developing locally delivered, extendedrelease products with potential to address therapeutic areas with high unmet medical need. DiffuSphere™ is a proprietary, polymer-based micro-sphere technology for targeted drug delivery designed to extend the duration of effect and deliver drugs in a hyper-localized fashion to specifically target the tissues that require treatment. Diffusphere is currently targeting both Eosinophilic Esophagitis (EOE) and Osteoarthritis in late-stage trials. The precision of Eupraxia's DiffuSphere™ technology is showing an ability to target only diseased tissues to deliver safety, efficacy, and duration. The potential uses in therapeutic areas may expand beyond inflammatory diseases into oncology where precision delivery of anti-cancer drugs may have the ability to alter the safety and efficacy conundrum of cancer care.

MEDICAL TECHNOLOGY

PRIVATE

EXACT IMAGING

Tuesday, May 6, 2025 | 11:30 AM **Room 104 B**



Exact Imaging is the world's leader in high-resolution micro-ultrasound systems enabling real-time imaging and guided biopsies in the urological market for prostate cancer. Exact Imaging's ExactVu[™] micro-ultrasound platform operates at 29 MHz and enables a new level of resolution with the benefits of ease of use, affordability, and is an extension of the current urological workflow. Using the Exact Imaging platform, urologists are able to visualize areas of interest in the prostate and target biopsies at those areas. For those cases where MRI might assist, the FusionVu™ micro-US/MRI fusion application operates on the ExactVu micro-ultrasound platform and facilitates fast, simple MRI fusion-based targeting with the guidance of the micro-ultrasound system's 70-micron real-time resolution. The ExactVu micro-ultrasound system including the FusionVu application has received regulatory approval in the European Union (CE Mark), the United States (FDA 510(k)), and Canada (Health Canada medical device license).

BIOTECHNOLOGY PRIVATE

FELDAN THERAPEUTICS

Tuesday, May 6, 2025 | 4:00 PM Room 104 A



Feldan is a clinical-stage pharmaceutical company specializing in the development of treatments based on the intracellular delivery of therapeutics. Its proprietary peptide-based technology, the Feldan Shuttle, enables the safe and efficient delivery of antisense oligonucleotides into cells, unlocking the potential for a new generation of therapies. Feldan's pipeline currently focuses on diseases affecting the skin and lungs.

BIOTECHNOLOGY

PRIVATE

FIND THERAPEUTICS

Tuesday, May 6, 2025 | 2:00 PM Room 104 A



Find Therapeutics is clinical-stage biopharmaceutical company dedicated to the development of next generation therapies to treat inflammatory autoimmune diseases. The company was launched in 2020 and is supported with investments from CTI Life Sciences, adMare BioInnovations, Domain Therapeutics and Investissment Québec and an exclusive license from SATT-Conectus and the University of Strasbourg on a technology and related know-how.

FLOSONICS MEDICAL

Monday, May 5, 2025 | 10:30 AM Rnnm 104 A



Flosonics Medical is a Canadian medical device company dedicated to enhancing patient care through innovative ultrasound technology. Founded in 2015, the company developed FloPatch, the world's first wireless, wearable Doppler ultrasound device that provides real-time hemodynamic assessments to guide precision fluid management in critically ill patients. This groundbreaking technology empowers clinicians to make informed decisions, optimizing treatment and improving patient outcomes.

MEDICAL TECHNOLOGY

PRIVATE

FLUID BIOMED

Tuesday, May 6, 2025 | 11:00 AM Room 104 R



Fluid Biomed Inc. is a clinical stage medical device company based in Calgary, Alberta, Canada, that is developing the next generation of stents to treat vascular disease. Founded by accomplished neurosurgeons with expertise in scientific research and clinical care, the company has created ReSolv™, the world's first bioabsorbable polymer-based neurovascular stent to cure brain aneurysms, which are a leading cause of stroke and disability worldwide.

PHARMACEUTICAL PRIVATE

FORUS THERAPEUTICS

Monday, May 5, 2025 | 3:30 PM Room 104 B



FORUS Therapeutics is a Canadian biopharmaceutical company dedicated to advancing differentiated, novel medicines for hematologic malignancies and other forms of cancer. Our mission is to bring solutions to Canadian cancer patients, caregivers, physicians and our partners by accelerating unique and important treatments that meaningfully enhance life. We currently have partnerships with Karyopharm Therapeutics, for XPOVIO, a unique oral compound used to treat Multiple Myeloma and with PharmaEssentia Corporation for BESREMI; a novel pegylated interferon for the treatment of Polycythemia vera, a rare blood disorder. Our growing portfolio has the opportunity to benefit thousands of Canadian patients now and in the future through ongoing clinical development and indication expansion. From Canada - For Canada.

PHARMACEUTICAL

TSX-V: WOLF

GREY WOLF ANIMAL HEALTH

GreyWolf

ANIMA HEATH

Monday, May 5, 2025 | 9:30 AM Room 104 B

Grey Wolf Animal Health Corp. is a diversified health company. Grey Wolf currently operates two business units: (1) Animal Health and (2) Pharmacy. The Animal Health business unit focuses on sourcing, in-licensing, acquiring, and commercializing branded and generic pharmaceutical, nutraceutical, and consumable products for the animal health market. The Pharmacy business unit compounds pharmaceuticals for the human and animal health markets in Canada. Over the last six years, the Company has grown organically, supported by the launch of over 15 products, and by three accretive acquisitions.

DIGITAL HEALTH TSX: AIDX

HEALWELL AI

Tuesday, May 6, 2025 | 10:00 AM **Room 104 C/D**

HEALWELL A

HEALWELL is a healthcare artificial intelligence (AI) company focused on preventative care. Our mission is to improve healthcare and save lives through the early identification and detection of disease. Using our own proprietary AI technology, we are developing and commercializing advanced clinical decision support systems that can help healthcare providers detect rare and chronic diseases, improve efficiency of their practice and ultimately help improve patient health outcomes.

PHARMACEUTICAL

TSX: HLS

HLS THERAPEUTICS

Monday, May 5, 2025 | 2:30 PM Room 104 B



Formed in 2015, HLS is a pharmaceutical company focused on the acquisition and commercialization of late-stage development, commercial stage promoted and established branded pharmaceutical products in the North American markets. HLS's focus is on products that address unmet needs in the treatment of psychiatric disorders and cardiovascular disease. HLS's management team is composed of seasoned pharmaceutical executives with a strong track record of success in these therapeutic areas and at managing products in each of these lifecycle stages.

INTELLIJOINT SURGICAL

Monday, May 5, 2025 | 11:00 AM Room 104 A



Intellijoint Surgical® develops and commercializes surgical planning & navigation solutions for total hip and knee joint replacements. It is committed to improving patients' lives by providing every Orthopaedic Surgeon and their Care Team, access to easy-to-use technology. Intellijoint's technology is used by top orthopaedic institutions and surgeons globally.

PHARMACEUTICAL

TSX: GUD

KNIGHT THERAPEUTICS

Monday, May 5, 2025 | 2:00 PM Room 104 B



Knight Therapeutics Inc. is a pan-American (ex-US) specialty pharmaceutical company focused on acquiring, in licensing, out-licensing, marketing, and commercializing innovative prescription pharmaceuticals in Canada and Latin America. Headquartered in Montreal, Knight has operations in Canada and in 10 countries in Latin America and has over 700 employees globally.

PHARMACEUTICAL PRIVATE

KYE PHARMACEUTICALS

Monday, May 5, 2025 | 4:00 PM Room 104 B



Kye is a growth-stage Canadian specialty pharmaceutical company committed to bringing value to Canadians by commercializing novel prescription medicines that may not otherwise be available to patients across Canada. Fueled by courage and agility, our corporate philosophy is rooted in the pursuit of innovation and driven by our entrepreneurial spirit. With a growing pipeline of novel medicines, Kye's portfolio spans a range of therapeutic areas including cardiology, psychiatry, pediatrics, rare diseases, hematology, and neurology. Kye Pharmaceuticals is a private company headquartered in Toronto focused on bringing medications to the Canadian market which fulfill clinically significant unmet needs. Kye is committed to licensing and launching medicines that matter by delivering better outcomes to our partners, Canadian healthcare professionals, and most importantly, patients across Canada.

DIGITAL HEALTH

PRIVATE

LEAGUE

Tuesday, May 6, 2025 | 1:30 PM Rnnm 104 C/D



Founded in 2014, League is a platform technology company powering next-generation healthcare consumer experiences. Payers, providers, consumer health partners and employers build on League's healthcare CX platform to deliver high-engagement, personalized healthcare experiences people love. League recently announced a \$95 million funding round led by TDM Growth Partners, backer of breakthrough platforms Square, Twilio and Slack, bringing the total funding to \$220 million. League is also among Deloitte's Technology Fast 500, CB Insights' Digital Health 150 and was named the Next Healthtech Unicorn by Accenture, among many other acknowledgements.

PHARMACEUTICAL

LSL PHARMA GROUP

Monday, May 5, 2025 | 10:30 AM Room 104 B



LSL Pharma Group Inc. is a Canadian integrated pharmaceutical company specializing in the development, manufacturing and marketing of high-quality sterile ophthalmic pharmaceutical products, as well as pharmaceutical, cosmetic and natural health products in solid, semi-solid and liquid forms. The companies that are part of LSL Pharma Group are Steri-Med Pharma Inc., Laboratoire LSL Inc., Virage Santé Inc. and Dermolab Pharma Ltd.

BIOTECHNOLOGY

TSX-V: MRVL

MARVEL BIOSCIENCES

Monday, May 5, 2025 | 3:30 PM Room 104 A



Marvel Biosciences Corp., and its wholly owned subsidiary, Marvel Biotechnology Inc., is a Calgary-based pre-clinical stage pharmaceutical development biotechnology company that utilizes a "drug redevelopment" approach to drug development. Historically, when a new class of drug is developed, it is optimized for a particular target, but typically only approved for a specific disease. Often, a new disease is identified which involves the same target, however, pending the remaining patent life, the originally approved drug may not have sufficient time left for it to be commercially viable to be developed for the new disease indication. Marvel develops new synthetic chemical derivatives of the original approved drug for the new disease indication. Patent protection is sought, as the new potential asset is developed by the Company. The Company believes the business model results in significantly less risk, cost and time to develop its assets compared to traditional biotechnology companies.

MEDEXUS PHARMA

Monday, May 5, 2025 | 11:00 AM **Room 104 B**



Medexus is a leading specialty pharmaceutical company with a strong North American commercial platform and a growing portfolio of innovative and rare disease treatment solutions. Medexus's current focus is on the therapeutic areas of hematology-oncology and allergy, dermatology, and rheumatology.

BIOTECHNOLOGY

TSX: MDNA

MEDICENNA **THERAPEUTICS**



Monday, May 5, 2025 | 2:30 PM Room 104 C/D

Medicenna is a clinical-stage immunotherapy company developing novel, highly selective IL-2, IL-4 and IL-13 Superkines and first-in-class Empowered Superkines. Medicenna's long-acting IL-2 Superkine, MDNA11, is a next-generation IL-2 with superior affinity toward CD122 (IL-2 receptor beta) and no CD25 (IL-2 receptor alpha) binding, preferentially stimulating effector T cells. MDNA11 is being evaluated in the Phase 1/2 ABILITY-1 Study (NCT05086692) as a monotherapy and in combination with pembrolizumab, Merck's (known as MSD outside the United States and Canada) anti-PD-1 therapy. Medicenna's IL-4 Empowered Superkine, bizaxofusp (formerly MDNA55) has FastTrack (FDA) and Orphan Drug (FDA/EMA) status and has been studied in 5 clinical trials enrolling >130 patients, including a Phase 2b trial for recurrent GBM. Medicenna's early-stage IL-2/IL-15 Super-antagonists. from its MDNA209 platform, are being evaluated for autoimmune and graft-versus host diseases. Medicenna's early-stage BiSKITs™ (Bifunctional SuperKine ImmunoTherapies) and the T-MASK™ (Targeted Metalloprotease Activated SuperKine) programs are designed to enhance the ability of Superkines to treat immunologically "cold" tumors.

MICROBIX BIOSYSTEMS

Tuesday, May 6, 2025 | 2:30 PM Room 104 B



Microbix Biosystems Inc. creates proprietary biological products for human health, with over 100 skilled employees and sales now targeting C\$2.0 million or more per month. It makes and exports a wide range of critical ingredients and devices for the global diagnostics industry, notably antigens for immunoassays and its laboratory quality assessment products (QAPs™) that support clinical lab proficiency testing, enable assay development and validation, or help ensure the quality of clinical diagnostic workflows. Its antigens drive the antibody tests of approximately 100 diagnostics makers, while QAPs are sold to clinical lab accreditation organizations, diagnostics companies, and clinical labs. Microbix QAPs are now available in over 30 countries, supported by a network of international distributors. Microbix is ISO 9001 & 13485 accredited, U.S. FDA registered, Australian TGA registered, Health Canada establishment licensed, and provides IVDR compliant CE marked products across the EU.

MEDICAL TECHNOLOGY

PRIVATE

MOLECULIGHT

Tuesday, May 6, 2025 | 10:00 AM Room 104 B



MolecuLight is the leader in in point-of-care fluorescence imaging, providing the only FDA Class II-cleared diagnostic device for detection of bacteria. Their innovative devices empower healthcare providers to quickly and accurately detect elevated levels of bacteria in wounds, surgical sites, and other injuries. This real-time visualization of bacteria that is linked to infection empowers clinicians to make informed treatment decisions. Early and accurate detection of bacteria leads to more targeted treatment plans. By optimizing treatment plans, MolecuLight technology helps to accelerate healing and reduce the risk of complications. The multi-modal device combines bacterial detection, wound measurement, and imaging capabilities into a single tool, streamlining workflows and improving documentation accuracy. Integrating seamlessly with electronic medical records, MolecuLight empowers clinicians to deliver the highest standard of care while optimizing their workflow.

MSH PHARMA

Tuesday, May 6, 2025 | 10:30 AM **Room 104 A**



MSH Pharma is a private Canadian company that manufactures and develops suppositories. vaginal ovules and liquid products. Within this specialty, we are known for having one of the largest manufacturing capacity in North America, both for brand-name and generic drugs.

BIOTECHNOLOGY

TSX-V: NGEN

NERVGEN PHARMA

Monday, May 5, 2025 | 10:00 AM Room 104 C/D



NervGen Pharma Corp. is a clinical-stage biotech company dedicated to developing innovative treatments to promote nervous system repair in settings of neurotrauma and neurologic disease. The company is testing the clinical efficacy of its lead molecule, NVG-291, in a Phase 1b/2a clinical trial in spinal cord injury and has initiated preclinical evaluation of a new development candidate, NVG-300, in models of ischemic stroke, amyotrophic lateral sclerosis (ALS) and spinal cord injury.

NEUPATH HEALTH

Tuesday, May 6, 2025 | 11:00 AM Room 104 C/D



NeuPath is a vertically integrated health care provider utilizing research, data-driven insights, technology, and interdisciplinary care to help restore function for patients impacted by chronic pain, spinal injuries, sport-related injuries, and concussions. With equity ownership in seventeen clinics in Ontario and Alberta, NeuPath is building out a large-scale network to better serve patients across Canada and the United States. NeuPath is focused on transforming the hope of a better life into the reality of a life more fully lived.

MEDICAL TECHNOLOGY

PRIVATE

NICOYA LIFESCIENCES

Tuesday, May 6, 2025 | 10:30 AM Room 104 B



Nicoya is a Canadian life sciences tools company specializing in innovative biosensor technology for the academic and biopharmaceutical sectors. In their mission to improve human life, Nicoya provides scientists with user-friendly and integrated solutions that accelerate label-free biomolecular analysis.

ORPYX

Tuesday, May 6, 2025 | 3:30 PM Room 104 R



The Orpyx® Sensory Insole system enhances standard custom orthotics with advanced multi-modal sensor technology for continuous remote monitoring, supported by a team of specialized nurses. The system tracks critical parameters like plantar pressure, temperature, activity, and adherence, essential for preventing debilitating foot complications in individuals with diabetes and neuropathy. By supporting effective foot and limb management, Orpyx aims to reduce wounds and amputations, an area that drives one-third of the direct cost of diabetes.

MEDICAL TECHNOLOGY

TSX-V: PINK

PERIMETER **MEDICAL IMAGING**



Monday, May 5, 2025 | 9:30 AM Rnnm 104 A

Based in Toronto, Canada and Dallas, Texas, Perimeter Medical Imaging AI is a medical technology company driven to transform cancer surgery with ultra-high-resolution, realtime, advanced imaging tools to address areas of high unmet medical need. Available across the U.S., our FDA-cleared Perimeter S-Series OCT system provides real-time, cross-sectional visualization of excised tissues at the cellular level. The breakthroughdevice-designated investigational Perimeter B-Series OCT with ImgAssist AI represents our next-generation artificial intelligence technology that is currently being evaluated in a pivotal clinical trial, with support from a grant of up to US\$7.4 million awarded by the Cancer Prevention and Research Institute of Texas.

PHARMACORP RX

Tuesday, May 6, 2025 | 2:30 PM Room 104 C/D



PharmaCorp Rx Inc. has acquired and continues to operate three Canadian-based pharmacies under the PharmaChoice banner. Through a Strategic Alliance Agreement, PharmaChoice Canada Inc. ("PCC") assigned PCRX the exclusive right-of-first refusal to acquire all PCC-bannered stores. This agreement provides PCRX with a robust acquisition pipeline, covering the \sim 1,100 independent pharmacies currently under the PCC banner, as well as future stores that join PCC's banner program, which is growing by \sim 40+ stores annually. Additionally, PCRX has the ability and intends to pursue acquisitions of non-PCC-bannered stores.

MEDICAL TECHNOLOGY

NASDAQ: PROF, TSX: PRN

PROFOUND MEDICAL

Tuesday, May 6, 2025 | 1:30 PM Room 104 B



Profound Medical Corp. is a medical technology company focused on a therapeutics platform that provides the precision of real-time Magnetic Resonance Imaging combined with the safety and ablation power of directional and focused ultrasound technology for the incision-free ablation of diseased tissue.

PROMIS NEUROSCIENCES

Monday, May 5, 2025 | 10:30 AM Room 104 C/D



ProMIS Neurosciences Inc. is a clinical stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). The Company's proprietary target discovery engine applies a thermodynamic, computational discovery platform - ProMISTM and Collective Coordinates - to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. PMN310, the Company's lead product candidate for the treatment of AD, is a differentiated, humanized monoclonal antibody that has been designed to specifically bind toxic A β oligomers and to not bind plaque or monomers. Oligomers are known to drive disease progression in AD and PMN310 appears to be the only antibody to selectively bind oligomers, which is expected to support better safety and efficacy. PMN 310 has successfully completed a Phase 1a clinical study and initiated a Phase 1b clinical trial in AD patients.

BIOTECHNOLOGY

PRIVATE

RADIANT BIOTHERAPEUTICS

Tuesday, May 6, 2025 | 3:00 PM Room 104 A



Radiant Biotherapeutics is a revolutionary antibody platform company leading the new frontier of multi-valent, multi-specific therapeutics to deliver transformative therapies for patients. Radiant's proprietary Multabody™ platform leverages avidity and multi-specifility simultaneously, to generate highly efficacious Multabodies with superior potency than other antibody platforms. These powerful Multabodies are a new class of biologics positioned to tackle complex, heterogenous diseases such as cancer, that often have challenging targets and mechanisms. Multabody™ production and manufacturing is flexible, modular and scalable, and leverages standard antibody CMC processes. The groundbreaking efficiency of the platform is driving a novel pipeline of mono-, bi- and trispecific biologics in multiple therapeutics areas. With offices in Toronto and Philadelphia, Radiant has forged multiple strategic partnerships that validate the Multabody™ platform's broad scientific and clinical utility.

BIOTECHNOLOGY PRIVATE

REVERB THERAPEUTICS



Tuesday, May 6, 2025 | 3:30 PM Room 104 A

Based in Vancouver, Reverb Therapeutics is the leader in creating precision medicine for the body's immune system. By using the body's natural endogenous cytokines, Reverb's Amplify•R™ platform avoids the systemic toxicity and immunogenicity normally associated with cytokine treatments. Reverb's bispecific antibodies help the body to amplify and redirect cytokines to tissues of interest, with potential to generate powerful medicines for cancer, autoimmune conditions, and other diseases. Elements of Amplify•R™ antibodies are reusable, allowing Reverb to rapidly scale its pipeline across multiple disease areas.

BIOTECHNOLOGY

TSX: MSCL

SATELLOS BIOSCIENCE

Monday, May 5, 2025 | 11:30 AM Room 104 C/D



Satellos is a clinical-stage drug development company dedicated to developing life-improving medicines to treat degenerative muscle diseases. Satellos has invented SAT-3247 as a first-of-its-kind, orally administered small molecule drug designed to restore skeletal muscle regeneration initially in Duchenne muscular dystrophy (DMD). Satellos has generated a significant body of preclinical evidence in DMD to support its discovery that correcting muscle stem cell polarity with SAT-3247 has the potential to restore skeletal muscle regeneration to repair and strengthen muscle that has been damaged. The Company's lead drug candidate, SAT-3247, is currently in clinical development as a potential disease-modifying treatment for DMD. Additionally, Satellos is leveraging its breakthrough research and proprietary discovery platform MyoReGenXTM, to identify degenerative muscle diseases where deficits in muscle regeneration occur that are amenable to therapeutic intervention for future clinical development.

SONIC INCYTES



Monday, May 5, 2025 | 10:00 AM Rnnm 104 A

Sonic Incytes is committed to enhancing patient care through innovative diagnostic solutions. The company's flagship product, Velacur[™], equips physicians with an advanced liver imaging tool to help manage the growing epidemic of fatty liver disease. Velacur offers real-time, Al guided quantification of the key markers for fatty liver disease: liver stiffness, attenuation and VDFF. With real-time results, a low up-front cost and Al guidance, VELACUR makes liver imaging at the point of care affordable and accessible.

HEALTHCARE SERVICES

PRIVATE

SPECIALTY MEDICAL PARTNERS



Tuesday, May 6, 2025 | 3:00 PM **Room 104 C/D**

Specialty Medical Partners (SMP) is a healthcare organization dedicated to providing exceptional patient care through a network of specialized clinics across the region. With a focus on creating a patient-centered experience. SMP partners with leading medical professionals to expand access to high-quality care, deliver clinical excellence, and drive continuous improvement in patient outcomes.

BIOTECHNOLOGY PRIVATE

SPECIFIC BIOLOGICS



Tuesday, May 6, 2025 | 2:30 PM Room 104 A

Specific Biologics Inc. is a venture-backed early-stage biotechnology company on a mission to develop novel gene editing technologies to treat diseases through efficient and precise genome editing. Our differentiated two-site Dualase® platform gene editors cut DNA in a way that optimally exploits the cell's naturally occurring DNA repair pathways. This enables two genome editing outcomes, precise DNA deletions to disrupt genes or increased repair to correct genes to target new therapeutic areas for genome editing. Specific is developing a pipeline of Dualase®-based therapeutics in areas of high unmet medical need.

HEALTHCARE SERVICES

PRIVATE

SRX HEALTH SOLUTIONS

Tuesday, May 6, 2025 | 3:30 PM Room 104 C/D



SRx operates as a Canadian healthcare service provider specializing in the Specialty Pharmacy segment of the pharmaceutical industry. Distinguishing itself as a National Specialty Pharmacy provider, SRx concentrates on overseeing a patient's healthcare journey, spanning from acute pharmaceutical needs to chronic and rare disease management. This unique focus positions SRx to deliver a more holistic and integrated solution, catering to the requirements of both patients and key healthcare stakeholders. Our all-encompassing end-to-end offerings include wholesale/distribution facilities, patient support programs, infusion clinics, retail pharmacies, co-designed clinical programs, clinical trials, and diagnostic services.

SYNAPTIVE MEDICAL

Tuesday, May 6, 2025 | 9:30 AM **Room 104 B**

Synaptive

Synaptive Medical Inc., a Toronto-based, high growth global medical technology company, solves surgical, imaging, and data challenges to improve the quality of human lives. Synaptive's integrated suite of products - bridging MRI, surgical planning, navigation, and robotic visualization - delivers patient-centric information with automated efficiency across all stages of clinical interventions.

PHARMACEUTICAL

NASDAQ: THTX, TSX: TH

THERATECHNOLOGIES

Monday, May 5, 2025 | 10:00 AM Room 104 B



Theratechnologies is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs.

BIOTECHNOLOGY PRIVATE

VENTUS THERAPEUTICS



Tuesday, May 6, 2025 | 1:30 PM Room 104 A

Ventus Therapeutics is a clinical-stage biopharmaceutical company deploying deep protein science expertise and a proprietary computational chemistry platform to develop novel small molecule therapeutics for immunology, inflammation, and neurology disorders. Ventus' ReSOLVE™ platform combines the latest advances in artificial intelligence/machine learning (Al/ML), structural biology, and biophysics to model the full spectrum of protein dynamics at an unparalleled resolution. Using ReSOLVE™, the company screened its first target in 2020, selected three development candidates in 2022, advanced its two wholly-owned product candidates into the clinic in 2023, and completed Phase 1 trials for both programs in 2024: VENT-03, a potent, selective, oral cGAS inhibitor, and VENT-02, a potent, brain-penetrant, oral NLRP3 inhibitor. In addition, Ventus has out-licensed VENT-01, a peripherally-restricted NLRP3 inhibitor in Phase 1, to Novo Nordisk A/S.

PHARMA SERVICES

PRIVATE

VIRICA BIOTECH

Tuesday, May 6, 2025 | 9:30 AM Room 104 A



Virica develops enhancers which optimize the manufacturing of viral vectors and cell and gene therapies, allowing developers to economically deploy their products at scale. Virica's Viral Sensitizer (VSE™) platform reduces production inefficiencies caused by innate cellular defences in manufacturing cells. Purpose formulated VSE™ combinations substantially increase manufacturing yields and reduce the cost of goods for a range of products, including vaccines, gene therapies, and cell therapies.

DIGITAL HEALTH TSX: VHI

VITALHUB

Tuesday, May 6, 2025 | 10:30 AM Rnnm 104 C/D



VitalHub is a leading software company dedicated to empowering health and human services providers globally. VitalHub's comprehensive product suite includes electronic health records, operational intelligence, and workforce automation solutions that serve over 1.000 clients across the UK. Canada, and other geographies. The Company has a robust two-pronged growth strategy, targeting organic opportunities within its product suite and pursuing an aggressive M&A plan. VitalHub is headquartered in Toronto with over 500 employees globally, across key regions and the VitalHub Innovations Lab in Sri Lanka.

HEALTHCARE SERVICES

TSX: WELL

WELL HEALTH TECHNOLOGIES



Tuesday, May 6, 2025 | 9:30 AM Rnnm 104 C/D

WELL's mission is to tech-enable healthcare providers. We do this by developing the best technologies, services, and support available, which ensures healthcare providers are empowered to positively impact patient outcomes. WELL's comprehensive healthcare and digital platform includes extensive front and back-office management software applications that help physicians run and secure their practices. WELL's solutions enable more than 38,000 healthcare providers between the US and Canada and power the largest owned and operated healthcare ecosystem in Canada with more than 200 clinics supporting primary care, specialized care, and diagnostic services. In the United States WELL's solutions are focused on specialized markets such as the gastrointestinal market, women's health. primary care, and mental health.

XEDITON PHARMACEUTICALS



Monday, May 5, 2025 | 3:00 PM Room 104 B

Xediton Pharmaceuticals is a privately-held specialty pharmaceutical company with a focus on meeting the needs of patients, physicians and partners. Xediton Pharmaceuticals is committed to developing, partnering and making available new and established medicines to promote the health of Canadians. Located in the Greater Toronto Area, Canada, Xediton Pharmaceuticals has products in Oncology, Anti-Infectives, Pain, CNS, GI, Ophthalmology, Renal and CV and has built strong strategic alliances with Global and International Healthcare and pharmaceutical companies.

DIGITAL HEALTH

PRIVATE

XYON HEALTH

Tuesday, May 6, 2025 | 4:00 PM Room 104 C/D



XYON Health Inc. (est 2021) is dedicated to applying cutting-edge science to combat hair loss so that men and women can safely regain their confidence. Our proprietary SiloxysSystem $^{\text{TM}}$ Gel was developed by doctors to precisely target effective medications where they're needed, reducing the risk of side effects. XYON strives to be the market leader for hair health through innovative solutions that deliver exceptional performance, without compromise.

BIOTECHNOLOGY PRIVATE

ZUCARA THERAPEUTICS



Tuesday, May 6, 2025 | 11:30 AM Room 104 A

Zucara Therapeutics is developing ZT-O1, a first-in-class, once-daily therapeutic to prevent hypoglycemia in people with T1D and insulin-dependent Type 2 diabetes. ZT-O1 is designed to inhibit somatostatin, a pancreatic hormone that impairs the glucagon response to hypoglycemia in people with these conditions. ZT-O1 is designed to restore glucagon secretion to prevent hypoglycemia, which could dramatically change diabetes disease management and improve both patient health and quality of life.

BIOTECHNOLOGY

NASDAQ: ZYME

ZYMEWORKS

Monday, May 5, 2025 | 1:30 PM Room 104 C/D



Zymeworks is a clinical-stage biotechnology company committed to the discovery, development, and commercialization of novel, multifunctional antibody-based therapeutics for difficult-to-treat diseases including cancer, inflammation, and autoimmune disease. Zymeworks engineered and developed zanidatamab, a HER2-targeted bispecific antibody, using its proprietary Azymetric™ technology. In 2022, Zymeworks entered into separate licensing agreements with BeiGene and Jazz Pharmaceuticals for zanidatamab's commercialization in different territories. The U.S. FDA granted accelerated approval of Ziihera® (zanidatamab-hrii) for previously-treated adults with unresectable or metastatic HER2-positive second-line biliary tract cancer (BTC). Ziihera® is the first and only U.S. approved dual HER2-targeted bispecific antibody for HER2-positive BTC. Zymeworks is advancing a pipeline of wholly-owned product candidates including antibody-drug conjugates and multispecific antibodies. Phase 1 studies for ZW171 and ZW191 are recruiting and ZW251 has IND and equivalent foreign applications planned for 2025.



ABOUT BLOOM BURTON & CO.



FOR 16 YEARS, BLOOM BURTON HAS SERVED CANADIAN HEALTHCARE INVESTORS AND COMPANIES.

Our team has deep knowledge in medicine, science, finance, and healthcare innovation, development and commercialization. We are the ideal group to help companies plan their capital market strategies, investigate the relevance of new biological pathways, consider new therapeutic indications and clinical designs, as well as catalogue and conduct due diligence on new products or companies for acquisition. By speaking with key companies and investors every day, we know what they are seeking and how to help.

We identify the most impactful companies for our investor network and we provide tailor-made support solutions for management teams and boards of healthcare companies.



PUBLIC OFFERING

US \$40,000,000

satellos

Lead Agent for the Offering for Satellos Bioscience Inc.

DECEMBER 2024

PRIVATE PLACEMENT

US \$7,700,000



Exclusive Agent for the Private Placement of Subscription Receipts for Conavi Medical Corp.

OCTOBER 2024

STRATEGIC ADVISORY



MAY 2024

M&A ADVISORY

Canadian-Based Global Health Company

SEARCHLIGHT

Financial Advisor to Searchlight Pharma Inc.

APRIL 2024

PRIVATE PLACEMENT

US \$150,000,000



Lead Agent to Cybin Inc.

MARCH 2024

FAIRNESS OPINON



DECEMBER 2023

STRATEGIC ADVISORY

MEDICENNA

NOVEMBER 2023

FINANCIAL ADVISORY

US \$1,075,000,000



inversago

Financial Advisor to Inversago Pharma

SEPTEMBER 2023

FAIRNESS OPINON

US \$2,000,000,000





JUNE 2023

M&A ADVISORY



Financial Advisor to Juno Pharmaceuticals Canada

MAY 2023

PRIVATE PLACEMENT



Lead Agent to Forus Therapeutics

MARCH 2023

STRATEGIC ADVISORY



2023

SERVICES

Our services help identify, cultivate and create investment opportunities in the healthcare sector on behalf of companies and investors.

From start-ups through commercial launches, we are active in all areas of the healthcare industry, including biotechnology, pharmaceuticals, medical devices, diagnostics, healthcare services, digital health, life science tools, animal health, nutrition and wellness.

Our six business services work cohesively to accelerate monetization for both company and investor clients.



Raising Capital & Financing

Sourcing equity and debt capital for private and public companies

M&A Advisory

Enabling monetization through strategic transactions

Equity Research

Influential opinions and insights on companies

Sales & Trading

Generating returns for investors

Strategic Advisory

Scientific and business advisory services

Company Creation

Establishing and incubating new healthcare companies

SPONSORS

























THANK YOU!





















TO OUR 2025 SPONSORS FOR YOUR GENEROUS SUPPORT!

NEEDENC

COMPANY PRESENTATIONS

Room 104 A

Room 104 B

Room 104 C/D

1X1 MEETINGS

Room 105

KEYNOTE ADDRESS AND PANEL DISCUSSIONS

Plenary Room 106/107

QUESTIONS OR LOST AND FOUND

Registration Booth


SUBMIT YOUR FEEDBACK!

Enjoying the conference or have suggestions to help us improve? We want to hear from you!

Scan the QR code and share your feedback:



NETWORK: BLOOM BURTON & CO. PASSWORD: BBHIC2025







#BBHIC2025



